Late-Stage Failures Force Neumora to Abandon Depression Drug Program
NMRA has more than doubled off its 52-week low of $0.716.
Summary
Neumora Therapeutics is discontinuing its depression drug program after the candidate failed to meet primary goals in two late-stage clinical trials. This is a significant setback for the small-cap biotech, eliminating a key potential revenue driver from its pipeline. The news adds pressure following recent financial reports that indicated a 12-month cash runway, partly sustained by dilutive capital raises and a recent repricing of executive stock options. This failure will likely increase scrutiny on the company's remaining pipeline and its ability to fund future development.
At the time of this announcement, NMRA was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $329.8M. The 52-week trading range was $0.72 to $3.65. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.